Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.
Scand J Gastroenterol
; 32(10): 1042-5, 1997 Oct.
Article
em En
| MEDLINE
| ID: mdl-9361178
ABSTRACT
BACKGROUND:
Endoscopic retrograde cholangiopancreatography was introduced in the early 1970s, making a more reliable diagnosis of primary sclerosing cholangitis (PSC) possible. Since then decreased survival and increased risk of cholangiocarcinoma have been reported. However, no population-based studies have quantified these outcomes.METHODS:
A population-based cohort of 125 patients with a verified PSC diagnosis was followed up through linkage to the Swedish Death Registry and the Swedish Cancer Registry for occurrence of death and cholangiocarcinoma.RESULTS:
The diagnosis of PSC was associated with a substantially decreased survival, with an overall 10-year survival of 68.8%. Patients with a diagnosis of inflammatory bowel disease (IBD) had a somewhat better prognosis, 71.8%, compared with 60% for patients without. Fourteen subsequent cholangiocarcinomas yielded a cumulative risk of 11.2% 10 years after diagnosis. Sex, duration of IBD, and colectomy influenced neither the survival nor the cholangiocarcinoma risk.CONCLUSION:
Patients with PSC have a substantially decreased survival, which is most pronounced among patients without IBD.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias dos Ductos Biliares
/
Ductos Biliares Intra-Hepáticos
/
Colangite Esclerosante
/
Colangiocarcinoma
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Scand J Gastroenterol
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Suécia